A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 Following ALLO-647 Containing Regimen in Subjects with Advanced or Metastatic clear Cell Renal Cell Carcinoma (ccRCC)
MD Anderson Study Status
ALLO-647, Fludarabine, Cyclophosphamide
This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647 to define a Phase 2 dose.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Stem Cell Transplantation
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.